Thursday, 26 March 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 26 March 2026
News

Pharma targets US$320B market

Posted 26 March 2026 PM

Sandoz is positioning itself to capture a significant share of the global biosimilar market, with up to 32 assets now under its wing following a new partnership with Samsung Bioepis.

While the financials have been kept under wraps, Sandoz announced a “major” license, development and commercialisation partnership agreement with Samsung Bioepis on up to five biosimilars.

To see the whole article, please login

Popular

PBS giant hangs on tight
Most expensive drug out of stock
Where Drs say pharma falls short
Companies chase listing changes
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home